Where can I buy Fezonatant?

Fizolinant regulates neuronal activity in the thermoregulatory center by blocking the binding of neurokinin B (NKB) to NK3 receptors on KNDy neurons in the hypothalamus, thereby reducing moderate to severe vasomotor symptoms related to menopause, such as hot flashes and night sweats. Its purchase channels and market layout show significant regional characteristics. Patients need to choose a procurement path based on drug accessibility, price sensitivity and compliance requirements, and be wary of legal risks and drug quality hazards caused by informal channels.

What are the purchasing channels for Fezonatant?

The purchasing channels are affected by the drug launch progress, medical insurance coverage and regional regulatory policies. Patients need to choose a compliant and economical purchasing path according to their own needs.

Hospital pharmacy channels

Patients can purchase drugs through hospitals in countries where Zonatant is marketed. They can obtain medical prescriptions after visiting the hospital. They can purchase drugs directly in the hospital pharmacy and use the drugs under the guidance of a doctor.

Online pharmacy channels

Some international online pharmacies provide overseas drug purchase services, which require prescriptions from overseas doctors and patient identity certificates. Before purchasing drugs, you need to confirm whether the platform has a drug business license and drug import qualifications.

Overseas drug purchase channels

Patients can directly go to overseas listed countries and purchase Fezonatan in hospitals or pharmacies in listed countries.

The marketing status of filazonatant

The global marketing process of filazonatant is closely related to the expansion of indications. Patients need to pay attention to the drug regulatory policies and medical insurance coverage of each country.

Global marketing progress

In May 2023, the U.S. FDA approved fezonatant for the treatment of moderate to severe vasomotor symptoms related to menopause, with the trade name Veozah. In March 2024, the EU EMA approved its marketing and included it in the rare disease drug list, suitable for female patients over 45 years old. Japan's Ministry of Health, Labor and Welfare approved its marketing in November 2024 for the treatment of refractory menopausal syndrome.

Domestic marketing process

Astellas Pharmaceuticals will submit a marketing application for Fazonatant to the State Food and Drug Administration in 2022, which is currently in the review stage. As the only pilot institution in China, Boao Super Hospital has completed more than 200 drug applications and no serious adverse reactions have occurred.

Price of Fezonatant

The price system of Fezonatant is affected by patent protection, production scale and regional pricing strategy. Patients need to choose a purchasing plan based on the treatment cycle and economic ability.

Prices of generic drugs of Lucius in Laos

The generic version of Fezonatant produced by Lucius Pharmaceuticals in Laos has a specification of 45mg×30 tablets/box and is priced at about US$108.

Price comparison of original drugs

The price of original drugs in the US market is US$3,800 per box. The price difference is mainly due to patent protection fees, distribution levels and exchange rate fluctuations. Patients should be aware that cross-border drug purchases may face the risk of drug recalls, and they should pay attention to safety warnings issued by FDA, PMDA and other agencies.

Patients need to continue to pay attention to the expiration date of patents and the progress of generic drug launches in order to obtain more economical treatment options.